- > Media & Investors
- > Media Relations
- > Press Releases
- > Announcement for partnership termination of sales and information provision of lyophilized hemophilus influenza type b vaccine “ActHIB®” in Japan
For Immediate Release
Daiichi Sankyo Company, Limited
Announcement for partnership termination of sales and information provision of lyophilized hemophilus influenza type b vaccine “ActHIB®” in Japan
Sanofi K.K. (Head Office: Shinjuku-ku, Tokyo; President: Jacques Nathan; hereafter “Sanofi”) and Daiichi Sankyo Company, Limited (Head Office: Chuo-ku Tokyo; President: Sunao Manabe; hereafter, Daiichi Sankyo) announced today that the partnership agreement for sales and information provision activities for the lyophilized hemophilus influenza vaccine type b “ActHIB®” will be terminated by the end of December 2018.
“ActHIB®” was developed and manufactured by Sanofi Pasteur in France, and Sanofi has had manufacturing and sales approval in Japan since January 2007. Under the partnership agreement between Sanofi and Daiichi Sankyo, Daiichi Sankyo has engaged in sales and information provision activities of “ActHIB®” since December 2008. Based on the agreement, both companies have contributed to improve public health in Japan; however, due to the expiration of the distribution and co-promotion agreement of “ActHIB®,” Sanofi and Daiichi Sankyo have agreed to terminate the partnership as of the end of December 2018.
From January 1, 2019, Sanofi will solely engage in sales and information provision activities of “ActHIB®.” Daiichi Sankyo will continue the distribution of “ActHIB®” until the end of December, 2019, and Sanofi will take it over from January 1, 2020. Both companies will cooperate to smoothly complete the transition.
In addition to improving public health in Japan through the supply of pharmaceuticals, including vaccines, both companies will continue to contribute to the prevention and treatment of diseases as well as to the improvement of public health.
Sanofi is dedicated to supporting people through their health challenges. As a global biopharmaceutical company focused on human health, we protect people with our vaccines and ease their pain and suffering with our innovative treatments. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Please visit the company’s website http://www.sanofi.co.jp for details of Sanofi K.K.
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases. For more information, please visit: www.daiichisankyo.com/
DAIICHI SANKYO COMPANY, LIMITED
Corporate Communications Department